Objectives: Pricing, affordability, and access are important deliberations around infectious disease interventions. Determining a fair price that not only incentivizes development but ensures value and access for patients is critical given the increasing global health crisis. Using ebola virus disease (EVD) as exemplar, we aim to elucidate the estimation of a value-based price (VBP) for a vaccine package and to consider how the price compares across selected countries that have experienced EVD outbreaks.

Methods: Using a dynamic transmission model, we assessed the cost-effectiveness of a vaccine package – composed of the vaccine, storage, maintenance, and administration - for vaccination toward herd immunity in 4 countries affected with EVD (Democratic Republic of Congo, Liberia, Sierra Leone, Uganda). Based on the cost-effectiveness metrics and using willingness-to-pay thresholds equal to varying percentages of the Gross Domestic Product (GDP), we demonstrated how a VBP is calculated using an adaptation of the “QALY-capped” approach.

Results: The VBP for the vaccine is directly proportional to both cost-effectiveness and GDP per capita- with higher cost-effectiveness and higher GDP per capita resulting in higher price ceilings compared to lower cost-effectiveness and lower GDP.

Conclusion: Despite the concerns with the “QALY-cap” approach, we illustrated that it is an easily comprehensible method for determining the VBP of a vaccine using a cost-effectiveness analysis. Choice of data, population characteristics, disease dynamics, and others are among factors that need to be considered when comparisons are made across countries.